Negoro-Cartilage_processed data.xlsx

Focal and
degenerative lesions of articular cartilage greatly reduce the patient’s
quality of life. Various therapies including surgical treatment have been
developed, but a definitive therapy is not yet known. Several cell
therapy products have already been developed and are available in the market.
In this study, we examined the clinical research trends related to cell therapy
products in the cartilage repair field based on data obtained from the
ClinicalTrial.gov website. Although this website does not provide comprehensive
results of clinical trials, it offers information on prospective clinical
trials, including work in progress, and thus allows for chronological analysis
of the data. We selected 203 studies related to the field of cartilage
regeneration from ClinicalTrial.gov. The results showed a shift in the clinical
translational trend in utilized cells from cartilage- and bone marrow- to
adipose tissue-based cells. Whereas the studies that used cartilage as the cell
source included many Phase III trials, fewer studies using bone marrow and
adipose tissue cells progressed to Phase III, suggesting that most clinical
developments using the latter sources have not been successful so far. One
product covered the entire period from the start of Phase I to the completion
of Phase III, with a time to completion of more than 100 months. Translational
trends in autologous chondrocyte implantation were also discussed. The use of ClinicalTrials.gov as the sole data source can
yield a perspective view of the global clinical translational trends, which has
been difficult
to observe up to this point.